Search hospitals > Michigan > Detroit
Children's Hospital of Michigan
Claim this profileDetroit, Michigan 48201
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Leukemia
Conducts research for Sickle Cell Disease
Conducts research for Brain Tumor
309 reported clinical trials
18 medical researchers
Summary
Children's Hospital of Michigan is a medical facility located in Detroit, Michigan. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Leukemia, Sickle Cell Disease, Brain Tumor and other specialties. Children's Hospital of Michigan is involved with conducting 309 clinical trials across 494 conditions. There are 18 research doctors associated with this hospital, such as Jeffrey Taub, MD, Stephanie A. Toll, Roland L. Chu, and Meret Henry, MD.Top PIs
Jeffrey Taub, MDWayne State University/Karmanos Cancer Institute8 years of reported clinical research
Studies Cancer
Studies Lymphoma
13 reported clinical trials
55 drugs studied
Stephanie A. TollChildren's Hospital of Michigan5 years of reported clinical research
Studies Brain Tumor
Studies Brain Cancer
8 reported clinical trials
21 drugs studied
Roland L. ChuChildren's Hospital of Michigan8 years of reported clinical research
Studies Neuroblastoma
Studies Ganglioneuroblastoma
8 reported clinical trials
24 drugs studied
Meret Henry, MDChildren's Hospital of Michigan8 years of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies Acute Myeloid Leukemia
8 reported clinical trials
37 drugs studied
Clinical Trials running at Children's Hospital of Michigan
Acute Lymphoblastic Leukemia
Testicular cancer
Leukemia
Wilms Tumor
Neuroblastoma
Cancer
Brain Tumor
Coronavirus
Burkitt Lymphoma
Acute Leukemia
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Single-Dose ZTI-01
for Pediatric Patients
Phase 1 study, a single dose of ZTI-01 given to pediatric subjects (under 12 years of age) who require antibiotic therapy to see what the body does to the drug (pharmacokinetics) and to compare if these effects are similar to those observed in adults at a 6g ZTI-01 dose. Study will help establish pediatric dosing in younger children by age cohort. This is a multiple-center, open-label, PK study of ZTI-01 (fosfomycin for injection) single dose scaled by allometric weight-modeling from an adult ZTI-01 dose of 6 grams. Eligible subjects must be receiving standard of care antibiotics for proven or suspected bacterial infection or for peri-operative prophylaxis surgery (in or out of hospital).
Recruiting1 award Phase 1
Cord Blood Units
for Blood Cancers
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Recruiting1 award N/A3 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Hospital of Michigan?
Children's Hospital of Michigan is a medical facility located in Detroit, Michigan. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Leukemia, Sickle Cell Disease, Brain Tumor and other specialties. Children's Hospital of Michigan is involved with conducting 309 clinical trials across 494 conditions. There are 18 research doctors associated with this hospital, such as Jeffrey Taub, MD, Stephanie A. Toll, Roland L. Chu, and Meret Henry, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.